
Lorlatinib and Diabetic Ketoacidosis An Emerging Class Effect?
Patients on lorlatinib should be monitored for hyperglycemia, regardless of autoantibody status. This case raises concerns about potential metabolic toxicities of ALK inhibitors beyond what is currently recognized.








